HC Wainwright Analysts Increase Earnings Estimates for IPSEN

IPSEN (OTCMKTS:IPSEY) – HC Wainwright boosted their FY2026 EPS estimates for shares of IPSEN in a report released on Tuesday, June 30th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of $3.62 per share for the year, up from their prior forecast of $3.49. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for IPSEN’s current full-year earnings is $3.77 per share. HC Wainwright also issued estimates for IPSEN’s FY2027 earnings at $4.05 EPS.

Other equities analysts also recently issued reports about the company. Zacks Research upgraded IPSEN to a “hold” rating in a research report on Friday, May 29th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold”.

IPSEN Stock Performance

Shares of OTCMKTS:IPSEY opened at $46.50 on Wednesday. The firm’s 50 day moving average is $47.25 and its two-hundred day moving average is $43.87. IPSEN has a 52 week low of $29.05 and a 52 week high of $51.10.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).